AUTHOR=Lee Heetae , An Jinho , Kim Jiyeon , Choi Dohyun , Song Youngcheon , Lee Chong-Kil , Kong Hyunseok , Kim Sang Bum , Kim Kyungjae 

TITLE=A Novel Bacterium, Butyricimonas virosa, Preventing HFD-Induced Diabetes and Metabolic Disorders in Mice via GLP-1 Receptor

JOURNAL=Frontiers in Microbiology

VOLUME=13

YEAR=2022

URL=https://www.frontiersin.org/journals/microbiology/articles/10.3389/fmicb.2022.858192

DOI=10.3389/fmicb.2022.858192

ISSN=1664-302X

ABSTRACT=<p>Knowledge of the impact of the gut microbiota on human health has increased, and modulation of the bacterial community is now considered a therapeutic target for various diseases. Certain novel bacterial species have probiotic properties associated with improvement in obesity and related metabolic disorders. The relative abundance of <italic>Butyricimonas</italic> spp. is correlated with metabolic parameters; however, the physiological role of <italic>Butyricimonas</italic> in metabolic improvement is unclear. In this study, live and heat-killed <italic>Butyricimonas virosa</italic> were administered to mice with high-fat diet (HFD)-induced obesity. Both live and heat-killed <italic>B. virosa</italic> ameliorated HFD-impaired body weight, serum glucose level, insulin resistance, and liver steatosis. Moreover, activation of the glucagon-like peptide-1 receptor (GLP-1R) and peroxisome proliferator-activated receptor α (PPARα) was observed in the liver, and the expression levels of insulin receptor substrate (IRS)-1, IRS-2, Toll-like receptor 5 (TLR5), and zonula occludens-1 (ZO-1) were upregulated in the ileum. Finally, we demonstrated that the effect of <italic>B. virosa</italic> treatment on glucose regulation may be linked to the upregulation of GLP-1R in the liver and is not a result of colonization of the gut by <italic>B. virosa</italic> or <italic>B. virosa</italic>-produced butyrate. Our results provide a rationale for the development of <italic>Butyricimonas</italic> spp.-based therapeutics and prophylactics for hyperglycemia.</p>